DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies announced that CEO Daniel Tassé will not participate in the previously scheduled fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, due to unavoidable travel disruption. The company will still participate in 1-on-1 investor meetings at the event in Miami, FL.

06/09/2026, 7:00 AM • GlobeNewswire

DBV Technologies révise sa participation à la 47ème conférence annuelle Global Healthcare organisée par Goldman Sachs

DBV Technologies announced that its management will participate in one-on-one investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 in Miami. However, CEO Daniel Tassé will not participate in the planned informal discussion due to unexpected travel disruptions.

06/09/2026, 7:00 AM • GlobeNewswire

DBV Technologies présente de nouvelles données positives issues de l’étude de phase 3 VITESSE, et un aperçu de l’étude THRIVE récemment initiée à l’occasion du Congrès de l’EAACI 2026

DBV Technologies announced positive results from its Phase 3 VITESSE study showing that the VIASKIN® Peanut patch demonstrated statistically significant efficacy versus placebo in peanut-allergic children aged 4-7 years with concurrent atopic conditions including asthma, food allergies, and atopic dermatitis. The company also presented the design of its Phase 2 THRIVE study evaluating the patch in infants aged 6-12 months with peanut allergy, aiming to enable unrestricted peanut consumption after three years of treatment.

06/08/2026, 4:35 PM • GlobeNewswire

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

DBV Technologies announced positive Phase 3 VITESSE study results showing the VIASKIN® Peanut Patch demonstrated statistically significant efficacy versus placebo in children aged 4-7 years with peanut allergy who also have atopic comorbidities such as asthma, food allergies, or atopic dermatitis. The company also previewed its newly initiated Phase 2 THRIVE study, which will evaluate the patch's efficacy in infants aged 6-12 months with peanut allergy over three years of treatment.

06/08/2026, 4:35 PM • GlobeNewswire

DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachide

DBV Technologies announced the first participant screening in the THRIVE phase 2 clinical trial evaluating the efficacy and safety of VIASKIN® Peanut patch in infants aged 6-12 months with peanut allergies. The study aims to enable ad libitum peanut consumption through early intervention immunotherapy, building on positive results from earlier trials in older children.

06/02/2026, 7:40 PM • GlobeNewswire

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

DBV Technologies announced the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in infants ages 6-12 months with peanut allergy. The study will assess whether the patch can enable ad lib (unrestricted) peanut consumption through epicutaneous immunotherapy (EPIT), building on positive results from earlier trials in older age groups.

06/02/2026, 7:40 PM • GlobeNewswire

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.

04/13/2026, 1:00 PM • GlobeNewswire

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026

DBV Technologies announced the filing of its 2025 Annual Report on Form 10-K and Universal Registration Document on March 26, 2026. The company reported full year 2025 financial results and provided a business update on its VIASKIN® Peanut Patch clinical development programs. As of March 31, 2026, the company had 296,042,447 total shares composing its capital with 295,914,379 net voting rights.

04/02/2026, 4:30 PM • GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

DBV Technologies announced the filing of its 2025 Annual Report on Form 10-K and Universal Registration Document as of March 31, 2026. The company reported full year 2025 financial results and provided a business update on its VIASKIN® Peanut Patch clinical development programs. As of the reporting date, the company had 296,042,447 total shares outstanding with 295,914,379 net voting rights.

04/02/2026, 4:30 PM • GlobeNewswire

DBV Technologies présente des données positives supplémentaires de l’étude de phase 3 VITESSE à l’occasion du congres annuel AAAAI

DBV Technologies announced positive additional data from the Phase 3 VITESSE study of its VIASKIN® Peanut patch for peanut-allergic children ages 4-7. The patch demonstrated statistically significant efficacy with 82.8% of treated children increasing their reactive dose by at least one level versus 48% in placebo, and 60.1% increasing by at least two levels versus 23.4% in placebo. The company plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2026.

02/28/2026, 2:25 PM • GlobeNewswire

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

DBV Technologies announced positive additional data from its Phase 3 VITESSE clinical trial of the VIASKIN® Peanut Patch for treating peanut-allergic children aged 4-7 years. The study met its primary endpoint with 46.6% of treated children becoming responders versus 14.8% in the placebo group. Key findings show 82.8% of treated children increased their eliciting dose by at least one step, compared to 48% in placebo, with the patch demonstrating consistent desensitization effects across patient subgroups. The company plans to submit a Biologics License Application to the FDA in the first half of 2026.

02/28/2026, 2:25 PM • GlobeNewswire

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

DBV Technologies announced €166.7 million in gross proceeds from the full exercise of ABSA and BS warrants issued in March 2025. The company states it is sufficiently funded to support operations and commercial preparedness for a potential U.S. launch of VIASKIN® Peanut patch in children aged 4-7 years, contingent on regulatory approval. The warrant exercises were triggered following positive topline results from the Phase 3 VITESSE trial announced in December 2025.

01/16/2026, 6:11 PM • GlobeNewswire

DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025

DBV Technologies announced it has received €166.7 million in gross proceeds from the full exercise of subscription warrants issued in March 2025. The company now has sufficient funds to support operations and commercial preparation for the potential U.S. launch of VIASKIN Peanut patch for children aged 4-7, pending regulatory approval. The company estimates its cash position will support operations for at least the next 12 months.

01/16/2026, 6:11 PM • GlobeNewswire

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025

DBV Technologies published updated information on its capital structure as of December 31, 2025, reporting 235,670,864 total shares and voting rights. The company also released a half-year report on its liquidity contract with ODDO BHF. The disclosure was made to comply with AMF regulations and corrected a previous publication from January 5, 2026 to account for employee stock plan exercises and prior financing operations.

01/12/2026, 4:00 PM • GlobeNewswire

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

DBV Technologies disclosed its total number of shares and voting rights as of December 31, 2025, reporting 235,670,864 total shares with 235,596,284 net voting rights. The company also published a half-year report on its liquidity contract with ODDO BHF. The disclosure was updated to account for earlier exercise of securities instruments related to employee stock ownership plans and warrants.

01/12/2026, 4:00 PM • GlobeNewswire